Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jan;79(2):229–235. doi: 10.1038/sj.bjc.6690038

Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells

M C Filion 1,2, P Lépicier 1, A Morales 3, N C Phillips 1,2
PMCID: PMC2362191  PMID: 9888462

Abstract

Intact mycobacteria and mycobacterial cell wall extracts have been shown to inhibit the growth of human and murine bladder cancer. Their mechanism of action is, however, poorly understood. Mycobacterium phlei mycobacterial cell complex (MCC) is a cell wall preparation that has mycobacterial DNA in the form of short oligonucleotides complexed on the cell wall surface. In this study, we have investigated the possibility that MCC has anti-cancer activity that is mediated by two different mechanisms – a direct effect on cancer cell proliferation and viability and an indirect effect mediated by the production of interleukin 12 (IL-12), a cytokine known to possess anti-cancer activity. We have found that, although MCC is a potent inducer of IL-12 and IL-6 synthesis in monocytes and macrophages either in vitro or in vivo, it is unable to induce the synthesis of either IL-12, IL-6 or granulocyte–macrophage colony-stimulating factor (GM-CSF) by the human transitional bladder cancer cell lines HT-1197 and HT-1376. MCC is not directly cytotoxic towards these cancer cells, but induces apoptosis as determined by nuclear DNA fragmentation and by the release of nuclear mitotic apparatus protein. Mycobacterium phlei DNA associated with MCC is responsible for the induction of apoptosis. Our results indicate that MCC directly effects bladder cancer cells by inhibiting cellular proliferation through the induction of apoptosis, and has the potential for an indirect anti-cancer activity by stimulating cancer-infiltrating monocytes/macrophages to synthesize IL-12. © 1999 Cancer Research Campaign

Keywords: apoptosis, bladder cancer cells, mycobacterial cell wall, granulocyte–macrophage colony-stimulating factor interleukin 6, interleukin 12

Full Text

The Full Text of this article is available as a PDF (126.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexandroff A. B., Black J., Esuvaranathan K., James K. Antiproliferative effect of IL-6 on transitional cell carcinoma of the bladder. Insight into mechanisms of bacillus Calmette-Guerin immunotherapy. Biochem Soc Trans. 1997 May;25(2):270S–270S. doi: 10.1042/bst025270s. [DOI] [PubMed] [Google Scholar]
  2. Bevers R. F., de Boer E. C., Kurth K. H., Schamhart D. H. Effects of isoniazid on the proliferation and cytokine production of bladder cancer cells in vitro induced by bacille Calmette-Guérin. Br J Urol. 1997 Jul;80(1):35–39. doi: 10.1046/j.1464-410x.1997.00211.x. [DOI] [PubMed] [Google Scholar]
  3. Brunda M. J., Luistro L., Warrier R. R., Wright R. B., Hubbard B. R., Murphy M., Wolf S. F., Gately M. K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993 Oct 1;178(4):1223–1230. doi: 10.1084/jem.178.4.1223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chen L., Chen D., Block E., O'Donnell M., Kufe D. W., Clinton S. K. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol. 1997 Jul 1;159(1):351–359. [PubMed] [Google Scholar]
  5. Chin J. L., Kadhim S. A., Batislam E., Karlik S. J., Garcia B. M., Nickel J. C., Morales A. Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol. 1996 Sep;156(3):1189–1193. doi: 10.1016/s0022-5347(01)65748-3. [DOI] [PubMed] [Google Scholar]
  6. Dive C., Evans C. A., Whetton A. D. Induction of apoptosis--new targets for cancer chemotherapy. Semin Cancer Biol. 1992 Dec;3(6):417–427. [PubMed] [Google Scholar]
  7. Esuvaranathan K., Alexandroff A. B., McIntyre M., Jackson A. M., Prescott S., Chisholm G. D., James K. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol. 1995 Aug;154(2 Pt 1):572–575. doi: 10.1097/00005392-199508000-00072. [DOI] [PubMed] [Google Scholar]
  8. Filion M. C., Phillips N. C. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta. 1997 Oct 23;1329(2):345–356. doi: 10.1016/s0005-2736(97)00126-0. [DOI] [PubMed] [Google Scholar]
  9. Hawkyard S. J., Jackson A. M., Prescott S., James K., Chisholm G. D. The effect of recombinant cytokines on bladder cancer cells in vitro. J Urol. 1993 Aug;150(2 Pt 1):514–518. doi: 10.1016/s0022-5347(17)35538-6. [DOI] [PubMed] [Google Scholar]
  10. Horie Y., Miura K., Matsui K., Yukimasa A., Ohi S., Hamamoto T., Kawasaki H. Marked elevation of plasma carcinoembryonic antigen and stomach carcinoma. Cancer. 1996 May 15;77(10):1991–1997. doi: 10.1002/(SICI)1097-0142(19960515)77:10<1991::AID-CNCR5>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  11. Ioachim-Velogianni E., Stavropoulos N. E., Kitsiou E., Stefanaki S., Agnantis N. J. HLA-DR antigen expression and lymphocyte subsets in transitional cell carcinoma of the urinary bladder. An immunohistological study on frozen sections. J Pathol. 1994 Nov;174(3):183–189. doi: 10.1002/path.1711740307. [DOI] [PubMed] [Google Scholar]
  12. Izquierdo M. A., Degen D., Sypek J. P., Von Hoff D. D. Antiproliferative effects of interleukin-12 treatment on human tumor colony-forming units taken directly from patients. Anticancer Drugs. 1996 May;7(3):275–280. doi: 10.1097/00001813-199605000-00006. [DOI] [PubMed] [Google Scholar]
  13. Kawasaki T., Tomita Y., Bilim V., Takeda M., Takahashi K., Kumanishi T. Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. Int J Cancer. 1996 Nov 15;68(4):501–505. doi: 10.1002/(SICI)1097-0215(19961115)68:4<501::AID-IJC16>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  14. Lagranderie M. R., Balazuc A. M., Deriaud E., Leclerc C. D., Gheorghiu M. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun. 1996 Jan;64(1):1–9. doi: 10.1128/iai.64.1.1-9.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lamm D. L. BCG in perspective: advances in the treatment of superficial bladder cancer. Eur Urol. 1995;27 (Suppl 1):2–8. doi: 10.1159/000475201. [DOI] [PubMed] [Google Scholar]
  16. Lamm D. L., Riggs D. R., Traynelis C. L., Nseyo U. O. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol. 1995 May;153(5):1444–1450. [PubMed] [Google Scholar]
  17. Lamm D. L., van der Meijden P. M., Morales A., Brosman S. A., Catalona W. J., Herr H. W., Soloway M. S., Steg A., Debruyne F. M. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992 Mar;147(3):596–600. doi: 10.1016/s0022-5347(17)37316-0. [DOI] [PubMed] [Google Scholar]
  18. Mallick B. B., Kishore S., Das S. K., Garg A. Nonspecific immunostimulation against viruses. Comp Immunol Microbiol Infect Dis. 1985;8(1):53–63. doi: 10.1016/0147-9571(85)90054-2. [DOI] [PubMed] [Google Scholar]
  19. Miller T., Beausang L. A., Meneghini M., Lidgard G. Death-induced changes to the nuclear matrix: the use of anti-nuclear matrix antibodies to study agents of apoptosis. Biotechniques. 1993 Dec;15(6):1042–1047. [PubMed] [Google Scholar]
  20. Mizutani Y., Okada Y., Yoshida O., Fukumoto M., Bonavida B. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. Cancer. 1997 Mar 15;79(6):1180–1189. doi: 10.1002/(sici)1097-0142(19970315)79:6<1180::aid-cncr17>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  21. Morales A. Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer. J Urol. 1984 Sep;132(3):457–459. doi: 10.1016/s0022-5347(17)49690-x. [DOI] [PubMed] [Google Scholar]
  22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  23. Nastala C. L., Edington H. D., McKinney T. G., Tahara H., Nalesnik M. A., Brunda M. J., Gately M. K., Wolf S. F., Schreiber R. D., Storkus W. J. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol. 1994 Aug 15;153(4):1697–1706. [PubMed] [Google Scholar]
  24. Newell M. K., Haughn L. J., Maroun C. R., Julius M. H. Death of mature T cells by separate ligation of CD4 and the T-cell receptor for antigen. Nature. 1990 Sep 20;347(6290):286–289. doi: 10.1038/347286a0. [DOI] [PubMed] [Google Scholar]
  25. Noguchi Y., Richards E. C., Chen Y. T., Old L. J. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2219–2223. doi: 10.1073/pnas.92.6.2219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Okamoto M., Hattori K., Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer. 1997 Jul 3;72(1):149–154. doi: 10.1002/(sici)1097-0215(19970703)72:1<149::aid-ijc21>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  27. Papapetropoulou M., Tsintzou A., Vantarakis A. Environmental mycobacteria in bottled table waters in Greece. Can J Microbiol. 1997 May;43(5):499–502. doi: 10.1139/m97-071. [DOI] [PubMed] [Google Scholar]
  28. Phillips N. C., Gagné L., Ivanoff N., Riveau G. Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens. Vaccine. 1996 Jun;14(9):898–904. doi: 10.1016/0264-410x(96)82949-5. [DOI] [PubMed] [Google Scholar]
  29. Pryor K., Goddard J., Goldstein D., Stricker P., Russell P., Golovsky D., Penny R. Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer. 1995 Apr;71(4):801–807. doi: 10.1038/bjc.1995.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Pryor K., Stricker P., Russell P., Golovsky D., Penny R. Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro. Cancer Immunol Immunother. 1995 Nov;41(5):309–316. doi: 10.1007/BF01517219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Rahman M. In vitro effects of high energy shock wave alone and combined with anticancer drugs on human bladder cancer cells. Urol Int. 1994;53(1):12–17. doi: 10.1159/000282624. [DOI] [PubMed] [Google Scholar]
  32. Rasheed S., Gardner M. B., Rongey R. W., Nelson-Rees W. A., Arnstein P. Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses. J Natl Cancer Inst. 1977 Apr;58(4):881–890. doi: 10.1093/jnci/58.4.881. [DOI] [PubMed] [Google Scholar]
  33. Sasaki A., Kudoh S., Mori K., Takahashi N., Suzuki T. Are BCG effects against urinary bladder carcinoma cell line T24 correlated with apoptosis in vitro? Urol Int. 1997;59(3):142–148. doi: 10.1159/000283049. [DOI] [PubMed] [Google Scholar]
  34. Shemtov M. M., Cheng D. L., Kong L., Shu W. P., Sassaroli M., Droller M. J., Liu B. C. LAK cell mediated apoptosis of human bladder cancer cells involves a pH-dependent endonuclease system in the cancer cell: possible mechanism of BCG therapy. J Urol. 1995 Jul;154(1):269–274. [PubMed] [Google Scholar]
  35. Stern A. S., Magram J., Presky D. H. Interleukin-12 an integral cytokine in the immune response. Life Sci. 1996;58(8):639–654. doi: 10.1016/s0024-3205(96)80003-8. [DOI] [PubMed] [Google Scholar]
  36. Stine K. C., Warren B. A., Becton D. L. Apoptosis induced by interleukin-12 measured by DNA electrophoresis and in situ end labeling in leukemia. Ann N Y Acad Sci. 1996 Oct 31;795:420–421. doi: 10.1111/j.1749-6632.1996.tb52710.x. [DOI] [PubMed] [Google Scholar]
  37. Tewari A. K., Sharma N. N., Rao J. R., Mishra A. K., Das S. K. Effect of Mycobacterium phlei on the development of immunity to Babesia bigemina. Vet Parasitol. 1996 Apr;62(3-4):223–230. doi: 10.1016/0304-4017(95)00873-x. [DOI] [PubMed] [Google Scholar]
  38. Voest E. E., Kenyon B. M., O'Reilly M. S., Truitt G., D'Amato R. J., Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995 Apr 19;87(8):581–586. doi: 10.1093/jnci/87.8.581. [DOI] [PubMed] [Google Scholar]
  39. Wyllie A. H., Kerr J. F., Currie A. R. Cell death: the significance of apoptosis. Int Rev Cytol. 1980;68:251–306. doi: 10.1016/s0074-7696(08)62312-8. [DOI] [PubMed] [Google Scholar]
  40. Zitvogel L., Lotze M. T. Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application. Res Immunol. 1995 Sep-Oct;146(7-8):628–638. doi: 10.1016/0923-2494(96)83041-0. [DOI] [PubMed] [Google Scholar]
  41. Zlotta A. R., Drowart A., Huygen K., De Bruyn J., Shekarsarai H., Decock M., Pirson M., Jurion F., Palfliet K., Denis O. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol. 1997 Jul;109(1):157–165. doi: 10.1046/j.1365-2249.1997.4141313.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Zlotta A. R., Drowart A., Van Vooren J. P., de Cock M., Pirson M., Palfliet K., Jurion F., Vanonckelen A., Simon J., Schulman C. C. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer. J Urol. 1997 Feb;157(2):492–498. [PubMed] [Google Scholar]
  43. Zou J. P., Yamamoto N., Fujii T., Takenaka H., Kobayashi M., Herrmann S. H., Wolf S. F., Fujiwara H., Hamaoka T. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol. 1995 Jul;7(7):1135–1145. doi: 10.1093/intimm/7.7.1135. [DOI] [PubMed] [Google Scholar]
  44. de Reijke T. M., Vos P. C., de Boer E. C., Bevers R. F., de Muinck Keizer W. H., Kurth K. H., Schamhart D. H. Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG). Urol Res. 1993;21(5):349–352. doi: 10.1007/BF00296835. [DOI] [PubMed] [Google Scholar]
  45. el-Demiry M. I., Hargreave T. B., Busuttil A., James K., Chisholm G. D. Immunohistochemical identification of lymphocyte subsets and macrophages in normal human urothelium using monoclonal antibodies. Br J Urol. 1986 Aug;58(4):436–442. doi: 10.1111/j.1464-410x.1986.tb09100.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES